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Abstract
Mouse embryonic stem cells (ESC) make cell fate decisions based on intrinsic and extrinsic factors. The decision of ESC to
differentiate to multiple lineages in vitro occurs during the formation of embryoid bodies (EB) and is influenced by cell-
environment interactions. However, molecular mechanisms underlying cell-environmental modulation of ESC fate decisions
are incompletely understood. Since adhesion molecules (AM) influence proliferation and differentiation in developing and
adult tissues, we hypothesized that specific AM interactions influence ESC commitment toward hematopoietic and
endothelial lineages. Expression of AM in the adherens, tight and gap junction pathways in ESC subpopulations were
quantified. E-cadherin (E-cad), Claudin-4 (Cldn4), Connexin-43 (Cx43), Zona Occludens-1 (ZO-1) and Zona Occludens-2 (ZO-
2) transcript levels were differentially expressed during early stages of hematopoietic/endothelial commitment. Stable ESC
lines were generated with reduced expression of E-cad, Cldn4, Cx43, ZO-1 and ZO-2 using shRNA technology. Functional
and phenotypic consequences of modulating AM expression were assessed using hematopoietic colony forming assays,
endothelial sprouting assays and surface protein expression. A decrease in E-cad, Cldn4, Cx43 and ZO-1 expression was
associated with less commitment to the hematopoietic lineage and increased endothelial differentiation as evidenced by
functional and phenotypic analysis. A reduction in ZO-2 expression did not influence endothelial differentiation, but
decreased hematopoietic commitment two-fold. These data indicate that a subset of AM influence ESC decisions to commit
to endothelial and hematopoietic lineages. Furthermore, differentially expressed AM may provide novel markers to
delineate early stages of ESC commitment to hematopoietic/endothelial lineages.
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Introduction
Stem cells from multiple sources are used for transplantation
therapy and tissue regeneration. For example, endothelial progen-
itor cells (EPC) are used to treat tissue ischemia, repair blood vessels
and relieve pulmonary hypertension in diabetes, vascular and
kidney diseases [1]. Hematopoietic stem cells (HSC) have been used
to treat blood disorders and influence immunological tolerance in
graft versus host disease [2]. Unfortunately, it is difficult to obtain
sufficient quantities of EPC or HSC for therapy by in vitro expansion
of these populations [1,3]. Embryonic stem cells (ESC) are capable
of indefinite self-renewal and under appropriate culture conditions
may potentially offer an infinite supply of progenitors. However, the
ability to reliably guide ESC toward hematopoietic or endothelial
lineages is complicated by a lack of understanding of key regulatory
signals/pathways involved in their proliferation and differentiation
decisions. Increased understanding of factors that guide early stages
of ESC commitment decisions towards hematopoietic and endo-
thelial lineages is an important step in developing strategies to direct
differentiation.
Embryoid bodies (EB), generated from ESC after removal of
leukemia inhibitory factor (LIF), are comprised of cells contribut-
ing to multiple lineages [4]. EB that promote hematopoietic and
endothelial differentiation of ESC in vitro are propagated in liquid
culture or methylcellulose [5,6]. However, the frequency of
endothelial and hematopoietic cells in these EB is extremely low
(9% CD34-expressing cells in day 8 murine EB [7]). Preferential
induction of ESC commitment to multiple different lineages can
be accomplished by varying culture conditions (refer to Keller [5]
for review). However, in the absence of exogenously added
cytokines that support hematopoietic commitment, EB generate
low numbers of hematopoietic and endothelial cells. Even in the
presence of a cytokine/growth factor-rich medium designed to
promote differentiation [8], ESC produce low numbers of
hematopoietic and endothelial cells. Propagation of stem cells
from fetal or adult hematopoietic tissues in vitro using differenti-
ating inducing cytokines invariably results in exhaustion of the
expansion capabilities of the stem cell population. Developing an
understanding of cell-cell and cell-environment interactions that
guide ESC towards hematopoiesis and endothelial cell commit-
ment may provide opportunities for increased expansion of
hematopoietic stem cells derived from ESC.
Junction proteins comprise one family of adhesion molecules
(AM) expressed in ESC. Several connexins, including Connexin-
43 (Cx43), form functional gap junctions when ESC are maintained
in an undifferentiated state; Cx43 is down-regulated during
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adherens junction protein, perturbs the formation of EB [11].
Junctionassociated proteins, suchasZona Occludens-1 and -2(ZO-
1 and ZO-2) are expressed in both mouse ESC [12] and endothelial
cells.WhilejunctionproteinsareexpressedduringEBdevelopment,
their role in hematopoietic and endothelial commitment decisions
of ESC is not well established. We explored the role of adhesion
molecules, and/or their downstream signaling or effector molecules
in specification of ESC to hematopoietic and endothelial lineages.
In this study, we quantified AM expression during EB formation
and lineage commitment in the absence of exogenous lineage-
specific cytokines and assessed phenotypic and functional con-
sequences of modulating levels of selected AM. We compared
transcript expression profiles of a panel of AM genes, shown
previously to be expressed in differentiating EB [10,12,13]. Quan-
titative analysis of AM gene expression profiles was performed on
Bry, Flk-1 and Scl expressing subpopulations, representing early
hematopoietic/endothelial commitment stages of EB. E-Cad,
Cx43, ZO-1 and ZO-2 were among the genes that were dif-
ferentially expressed during lineage commitment. The extent to
which the AM encoded by these genes modulate ESC commitment
to hematopoietic and endothelial lineages was assessed using RNAi
technology coupled with functional assays. These data are the first
to demonstrate that modulation of AM expression in ESC perturbs
early hematopoietic and endothelial commitment decisions. Fur-
thermore, we show that differentially expressed AM may be useful
to further discriminate phenotypes of transitional stages of early
hematopoietic and endothelial differentiation.
Results
AM are differentially expressed during EB development
Gene expression profiles of a panel of AM were measured in
developing EB (Table S1). Since developing EB are comprised of
multiple lineages, we used differentiation associated markers and
multivariate flow cytometric analysis to discriminate and sort
Bry+, Flk-1+ and Scl+ subpopulations prior to quantifying AM
gene expression using qPCR. These populations were discrimi-
nated using Bry-linked GFP expression, Scl-linked LacZ expres-
sion and a Flk-1-specific monoclonal antibody. Bry, Flk-1 and Scl
expression levels in EB peaked at day 4, 5 and 6, respectively
(Figure 1). Subpopulations were isolated at time periods when Bry,
Flk-1 and Scl were highly expressed. Thus, committed mesoderm
GFP+ cells in Bry-GFP EB were sorted at day 4, Flk-1+ cells
undergoing early hematopoietic and endothelial differentiation
were sorted from day 5 EB generated from D3-ESC, and Scl-
expressing subpopulations, containing cells that are committed to
hematopoiesis, but have not fully differentiated, were sorted from
day 6 EB generated from Scl-LacZ ESC. Transcript levels of 21
cell adhesion-associated genes in the sorted populations were
differentially expressed in one or more subpopulations (Table 1;
Figure 2A). Expressed genes in the Bry+, Flk-1+ or Scl+ subpopula-
tions were categorized according to Gene Ontology (GO) classifica-
tion. Junction molecules were differentially expressed with the
greatest frequency (62% of populations screened) in comparison to
remaining GO categories, in which 13–58% of populations
expressed 2-fold or greater increased/decreased transcript levels.
Junction molecule expression in Bry+, Flk-1+ and Scl+ subpopu-
lations varied 9–20 fold compared to cells that did not express Bry,
Flk-1 or Scl. For example, E-cad expression was 20-fold less in Flk-
1+ cells in day 5 EB compared to cells that did not express Flk-1 in
the same EB. E-cad was 9-fold higher in Scl+ cells compared with
Scl2 cells in day 6 EB (Figure 2B). These data suggest that E-cad,
Cx43, ZO-1 and ZO-2 expression are associated with commitment.
While these data suggest a relationship between expression of these
AM and commitment, the functional role of these AM in the
commitment decisions were evaluated using functional assays.
ESC lines with down-regulated expression of junction
molecules
The functional role of E-cad, Cx43, ZO-1 and ZO-2 in ESC
commitment decisions was investigated by modulating gene
expression levels using RNAi technology and assessing the
consequences of the modulation using functional assays. D3-ESC
were modified using lentiviral constructs with shRNA sequences
specific to E-cad, Cx43, ZO-1 and ZO-2. Each construct
expressed GFP to fluorescently label cells infected with lentiviral
particles (Figure S1). Knockdown cells lines, Kd-E-cad, Kd-Cx43,
Kd-ZO1 and Kd-ZO2, were characterized at transcript and
protein levels and evaluated for retention of pluripotency.
Transduced GFP+ cells comprised greater than 95% of the viable
cell population for multiple generations (Figure S2A) for each
construct. GFP expression was also stable for multiple generations.
To confirm that modulation of these AM did not affect
pluripotency of ESC, expression of SSEA-1 and Oct-4, markers
associated with murine ESC pluripotency, were quantified flow
cytometrically. SSEA-1 and Oct-4 were expressed at similar levels
in D3-ESC and engineered ESC lines propagated in ESC medium
(Figure S2C, S2D).
AM transcript expression levels were quantified in engineered
ESC lines using RT-qPCR (Figure 3A). The expression of E-cad,
Cx43, ZO-1 and ZO-2 was reduced in transduced ESC
populations compared to untransduced D3-ESC approximately
2–4-fold. Western blot analysis confirmed decreased expression of
E-cad, Cx43 and ZO-2 at the protein level in knockdown ESC
lines (Figure S3A). Inadequate antibody quality precluded
confirmation of the knockdown of ZO-1 at the protein level; even
through transcript was clearly reduced. Specificity of shRNA effect
was verified by qPCR of target gene expression in ESC expressing
scrambledshRNAsequences(Scram-GFP)(FigureS3B).Expression
Figure 1. Expression of markers of early transitional stages of
hematopoietic and endothelial differentiation is temporally
regulated. Bry-GFP, D3-ESC and Scl-LacZ ESC were differentiated in EB
media for 8 days and analyzed flow cytometrically for expression of Bry,
Flk-1 and Scl, respectively. Non-viable cells were excluded based on
propidium iodide (PI) fluorescence. Error bars represent standard
deviation with n=3.
doi:10.1371/journal.pone.0023810.g001
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Cx43, ZO-1 or ZO-2.
Knockdown of junction molecules influence
differentiation decisions in ESC
Hematopoietic/Endothelial Progenitors. We next
examined effects of modulating E-cad, Cx43, ZO-1 and ZO-2
levels in ESC differentiation toward hematopoietic and endothelial
lineages. Perturbations in early hematopoietic/endothelial com-
mitment were assessed by quantifying numbers of cells committing
to a hematopoietic/endothelial progenitor, Flk-1+ progenitor. The
frequency of Flk-1+ progenitors in engineered ESC with reduced
E-cad, Cx43 and ZO-1 levels in day 5 EB was similar to controls
(Figure 3B). The temporal profile of Flk-1 expression over a 6 day
period in the engineered ESC lines was also comparable to D3-
ESC (data not shown). In contrast, reduced ZO-2 expression in
Kd-ZO2 ESC resulted in approximately a 2-fold decrease in the
Flk-1+ progenitor population in day 5 EB compared to D3-ESC.
These data suggest that while E-cad, Cx43 and ZO-1 levels have
minimal effects on the frequency of Flk-1+ progenitor cells, ZO-2
may be involved in the commitment to Flk-1+ progenitor cells.
Hematopoietic differentiation. Evidence that modulation
of AM expression influences hematopoietic commitment was
investigated using 3 endpoints: expression of hematopoietic TF,
Runx1, Gata1 and Scl, identification and enumeration of CD45+
hematopoietic cells, and myeloid colony forming assays. The
expression of hematopoietic TF was quantified in developing EB
(Figure 4A). A decrease in E-cad expression resulted in a 3-fold
reduction in Runx1, Gata1 and Scl expression. Reduced levels of
Cx43 resulted in 2–8-fold decreases in levels of Runx1, Gata1 and
Scl. Knockdown of ZO-1 and ZO-2 reduced hematopoietic TF
expression 3–7-fold and 4–9-fold, respectively. The frequency of
cells expressing CD45, an extracellular marker expressed on the
surface of most hematopoietic cells, is an indication of hematopoietic
differentiation commitment. Reduced expression of E-cad, Cx43,
ZO-1 and ZO-2 levels was associated with an approximately 2-fold
reduction in the frequency of CD45+ cells (Figure 4B). Additionally,
the frequency of CD45+ cells in day 11 EB is linearly correlated
with expression levels of hematopoietic TF (Figure 4C). Another
indicator of hematopoietic commitment is the ability to form
myeloid colonies. The number of colony forming units (CFU) was
decreased approximately 2-fold in ESC lines with reduced E-cad,
Cx43 and ZO-2 compared to D3-ESC (Figure 4C). The decrease
was most pronounced incells undergoing macrophage commitment
(CFU-M). The frequency of CFU-M was decreased in Kd-E-cad
and Kd-Cx43 approximately 2-fold and in Kd-ZO2 greater than 3-
fold. These data suggest hematopoietic commitment is influenced
by expression of these junction molecules.
Endothelial differentiation. Quantitative measurements of
two endothelial associated receptors (Tie1 and Tie2), as well as
Table 1. Adhesion molecules are differentially expressed during hematopoiesis.
Gene Bry+ Flk-1+ Scl+
Membrane
Associated
Abcg2 N/S N/S 2.27+/20.51
App1 N/S N/S 3.43+/20.13
Bin1 N/S N/S 2.57+/21.81
Hematopoietic
Lineage
Cd44 N/S N/S 0.37+/20.01
Cd81 N/S 2.32+/20.13 N/S
Ly75 2.46+/20.04 N/S N/D
Junction
Molecule
E-cad 0.22+/20 0.05+/20.01 8.93+/23.18
Cldn4 0.23+/20.03 0.1+/20 0.44+/20.05
Cldn6 0.35+/20.03 N/D N/S
Cx31 0.28+/20.08 0.19+/20.06 N/S
Cx43 N/S N/S 3.86+/20.28
ZO-1 N/S 2.07+/20.22 N/S
ZO-2 0.34+/20.06 0.52+/20.02 2.83+/20.1
Extracellular
Matrix
Collagen4 N/S 4.64+/20.16 0.51+/20.03
Nidogen N/S 2.56+/20.28 N/S
Thrombospondin1 0.54+/20.07 0.39+/20.04 3.74+/20.46
Cell Adhesion
Molecule
ICAM 0.56+/20.09 N/S 0.21+/20.07
Receptor-
Ligand
Ddr1 0.3+/20.01 0.37+/20.02 N/D
Integrin B4 N/S N/D 0.41+/20.03
c-Kit 0.28+/20.01 N/S 4+/20.16
Wnt3 0.16+/20.01 N/S 4.15+/21.46
Transcript expression profiles of AM were generated using RT-qPCR from discrete transitional stages of early hematopoietic/endothelial development. Expression levels
in one or more subpopulations, Bry+, Flk-1+ and Scl+, were up- or down-regulated 2-fold or greater relative to Bry2, Flk-12 and Scl2 subpopulations, respectively. (N/
D=not determined; N/S=not significant; greater than 2-fold difference).
doi:10.1371/journal.pone.0023810.t001
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manipulation on endothelial development. Tie1 expression was
decreased approximately 2-fold in Kd-ZO2; whereas expression in
the other Kd-ESC lines was similar to control D3 (data not
shown). Tie2 expression was similar to D3-ESC for Kd-ESC
lines. Differentiation of ESC in the presence of endothelial lineage-
specific cytokines generates EB with sprouts (Figure 5A). Reduc-
tion of E-cad, Cx43 and ZO-1 expression increased the frequency
of EB with endothelial sprouting approximately 2-fold (Figure 5B),
and the number of sprouts on each EB by approximately 2-fold
(Figure 5C). Knockdown of ZO-2 did not significantly influence
the frequency of EB generating endothelial sprouts; however, there
was an approximately 2-fold increase in number of sprouts on
each EB. Tie1/2 data and the sprouting assays suggest that E-cad,
Cx43, ZO-1 and ZO-2 expression influence endothelial cell
differentiation from ESC derived progenitors.
Discussion
Cell-cell interactions are known to regulate transcriptional
machinery for proliferation and development in multiple systems
[14,15,16]. However, the contributions of cell surface mediated
protein signaling inESCfate decisionsareincompletelyunderstood.
Understanding the molecular signaling that influences commitment
decisions is important in developing strategies to guide ESC
commitment for regenerative therapies. Since AM are known to
have major roles in cell differentiation during embryonic develop-
ment [17,18,19,20], we explored the contributions of AM in ESC
commitment decisions to hematopoietic/endothelial lineages. We
Figure 3. ESC with knockdown of junction molecules by shRNA
maintain ability to differentiate to Flk-1 cells. A) shRNA
constructs efficiently silence endogenous mRNA in mESC. Quantitative
RT-PCR was performed on GFP expressing cells generated with lentiviral
constructs containing shRNA specific to E-Cadherin, Cx43, ZO1 and ZO2
to analyze transcript expression level. Samples were normalized to
GAPDH and expressed relative to transcript levels in untransfected D3-
ESC (dashed line). Error bars represent standard deviation of n=3
samples. B) Flk-1 expression does not significantly differ in knockdown
ESC lines. ESC lines stably expressing shRNA sequences specific to E-
Cad, Cx43, ZO-1 and ZO-2 and ESC lines with increased knockdown
levels of E-Cad and ZO-1 were differentiated in EB for 5 days and Flk-1
expression was analyzed flow cytometrically using anti-Flk-1 conjugated
to PE. Non-viable cells were excluded based on fluorescence of DAPI.
Paired t-tests with D3-ESC were performed with n=7 (Kd-E-cad, Kd-
Cx43, Kd-ZO-1) or n=6 (Kd-ZO-2). * p,0.05; *** p,0.0005. Error bars
represent standard error of the mean.
doi:10.1371/journal.pone.0023810.g003
Figure 2. AM are differentially expressed in early hematopoi-
etic and endothelial subpopulations of developing EB. Quan-
titative analysis of gene expression was performed on populations of
ESC differentiated in EB. Cells were sorted by FACS based on expression
of Bry for mesodermal commitment, Flk-1 for hematopoietic and
endothelial precursors and Scl for early hematopoietic cells. RNA was
extracted and quantitative RT-PCR was performed. A) 21 genes were
analyzed. Heat map was generated with Heatmap Builder (http://
ashleylab.stanford.edu/tools_scripts.html). B) Samples are normalized to
GAPDH and relative quantification is reported as percent of control
(expression from sorted cell populations negative for expression of Bry,
Flk-1 and Scl, respectively). Dashed line represents 2-fold increase/
decrease in transcript expression level. (n=3 for each sample; error bars
represent standard deviation).
doi:10.1371/journal.pone.0023810.g002
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proteins, cell adhesion molecules (CAM), hematopoietic lineage
markers, junction molecules, receptors and other membrane
associated proteins in ESC proliferation/differentiation and the
functional consequences of manipulating AM expression levels on
hematopoietic and endothelial commitment. Previous studies of
expression profiling, using microarray and proteomic analysis, of
murine ESC identified expressed AM [10,12,13] in ESC. While
these data demonstrate the AM are expressed during ESC culture,
the functional role of individual AM in influencing ESC
commitment decisions was not investigated. The ability to
effectively direct differentiation of ESC for therapy will require
understanding the complex cell-environment signaling pathways
that influence commitment decisions. ESC differentiation towards
the hematopoietic lineage is challenging, typically generating only
low numbers of hematopoietic cells [7]. While hematopoietic
commitment can be increased by addition of cytokines [8],
hematopoietic differentiation is still low and, addition of cytokines
Figure 4. Hematopoietic potential decreases in ESC with down-regulation of junction molecules. A) Knockdown ESC lines were
differentiated in EB for 9 days. RNA was extracted from GFP+ cells and quantitative RT-PCR was performed using SYBR Green and primers for
hematopoietic transcription factors Gata1, Runx1 and Scl. Error bars represent standard deviation of n=3 samples. B) ESC lines stably expressing
shRNA sequences specific to E-cadherin, Cx43, ZO-1 and ZO-2 were differentiated in EB for 11 days. CD45 expression was analyzed flow cytometrically
using anti-CD45 conjugated to PerCP-Cy5.5. Non-viable cells were excluded based on DAPI fluorescence. Paired t-tests were performed with D3-ESC
for n=7 (Kd-Cx43) and n=6 (Kd-E-cad, Kd-ZO1 and Kd-ZO2) (* p,0.05; ** p,0.005). Error bars represent standard error of mean. C) TF expression
level linearly correlates with decreased frequency of CD45+ cells. Gata1: R
2=0.87; Runx1: R
2=0.91; Scl: R
2=0.69. D) Day 5 EB with knockdown of E-
cadherin, Cx43, ZO-1 and ZO-2 were dissociated and replated as single cells to determine colony forming potential. Hematopoietic colonies were
scored after 12 days in methylcellulose media for presence of granulocyte colony forming units (CFU-G), macrophage colony forming units (CFU-M),
erythroid burst forming units (BFU-E), bipotent progenitors of granulocyte and macrophages (CFU-GM) and multipotent progenitors of these myeloid
lineages (CFU-mix). Error bars represent standard error of the mean for n=4 plates.
doi:10.1371/journal.pone.0023810.g004
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reducing usefulness for sustained therapy. Since AM are differen-
tially expressed after LIF removal, we explored whether manipu-
lation of AM expression influenced ESC commitment to hemato-
poietic and endothelial lineages.
EB are comprised of multiple transitional stages and lineages
[4], thus reduction of heterogeneity by subpopulation isolation
facilitates exploration of AM contributions to early hematopoietic/
endothelial lineage commitment. Early hematopoietic/endothelial
differentiation proceeds through defined stages of commitment.
ESC undergoing commitment to the mesoderm lineage express
the TF Bry [21,22]. A VEGF receptor, Flk-1, is expressed in a
subpopulation of Bry+ cells which are progenitors to early
endothelial and hematopoietic cells [23,24] and Flk-1+ cells that
express Scl are committed to hematopoiesis [25]. We used Bry,
Flk-1 and Scl expression to discriminate subpopulations in
developing EB. We show that temporal oscillations in Bry, Flk-1
and Scl expression during EB development are consistent with
those reported previously [22,26,27].
Junction molecules, including E-cad, Cx43, ZO-1 and ZO-2,
were among the 21 AM whose levels changed preferentially in EB
subpopulations expressing Bry, Flk-1 or Scl. E-cad is present in
adherens junctions, which indirectly link the cytoskeletons of
adjacent cells [28]; ZO-1 and ZO-2 are associated with tight
junction complexes, which generate a permeability barrier and
activate intracellular signaling responses that suppress cellular
proliferation [15]; Cx43 forms gap junctions, which allow second
messengers to pass between cells through the cytosol [9]. The
temporal and quantitative variation of E-cad, Cx43, ZO-1 and
ZO-2 expression during EB formation in culture conditions that
support hematopoietic and endothelial commitment suggest a role
for these proteins in ESC differentiation.
The effects of modulating E-cad, Cx43, ZO-1 and ZO-2
expression on hematopoietic and endothelial commitment poten-
tial of manipulated ESC were investigated to establish genotype-
phenotype relationships of these AM. Knockdown ESC lines were
engineered using RNAi stably introduced into the ESC genome
using lentiviral transduction. Although clonal analysis is preferable
in determining the role of AM in hematopoietic/endothelial
commitment, culture of ESC at low density often results in loss of
pluripotency. To reduce the heterogeneity in lentiviral transduc-
tion efficiency, transduced ESC were sorted based on GFP
expression to generate ESC lines with greater than 95% of cells
containing incorporated shRNA sequences. Using engineered
ESC lines, we demonstrated that reduced levels of E-cad, Cx43,
ZO-1 and ZO-2 had minimal influence on the frequency of SSEA-
1 expressing cells or level of Oct-4 expression, markers associated
with ESC pluripotency. These data suggest that pluripotency (as
assessed by SSEA-1 and Oct-4 expression) is unaffected by
manipulation of these AM.
If AM modulations affect the decision of ESC to differentiate
into a Flk-1+ progenitor, then the number and/or timing of Flk-1
expressing engineered ESC during EB development would be
altered. A reduction in E-cad, Cx43 and ZO-1 expression did not
appear to affect the frequency of Flk-1+ cells. However, these same
AM appeared to have a more prominent role in influencing
intermediate and later stages of hematopoietic commitment
because Kd-E-cad, Kd-Cx43 and Kd-ZO1 ESC showed reduced
expression of hematopoietic TF, as well as a lower frequency of
cells expressing CD45, present on cells committed to hematopoi-
esis [4] (Figure 4). These data suggest that Gata1, Runx1 and Scl
expression, associated with intermediate stages of hematopoietic
commitment are modulated by E-cad, Cx43 and ZO-1 expression.
The reduction in TF expression in Kd-E-cad, Kd-Cx43 and Kd-
ZO1 was paralleled with a decrease in the number of CFU,
particularly CFU-M. Hematopoietic commitment decreased in
engineered Kd-Cx43 ESC by approximately 2-fold, as evidenced
by frequency of CD45+ cells and CFU. The reduction in
hematopoietic commitment in Kd-Cx43 is consistent with data
reported by Cancelas, et al. [29] who observed a reduction in
hematopoiesis in fetal liver of Cx43
2/2 embryos particularly
CFU-GM and BFU-e (40–50% decrease). Hematopoiesis is not
completely inhibited in Cx43
2/2 embryos, suggesting interactions
between multiple proteins and/or pathways in hematopoietic
commitment. Since the knockdown of AM with shRNA sequences
does not completely abrogate gene expression in ESC, a more
extensive knockdown AM in ESC would be predicted to have a
larger impact on hematopoietic/endothelial commitment. Al-
though our knockdown was not complete (33% of control
expression), we observed decreased frequency of CD45+ cells
(48% of control), CFU-GM (48% of control) and BFU-e (68% of
Figure 5. Endothelial commitment is increased in ESC knock-
down lines. A) ESC lines stably expressing shRNA sequences specific to
E-cadherin, Cx-43, ZO-1 and ZO-2 were differentiated in Collagen I with
100 ng/ml bFGF and 50 ng/ml VEGF for 11 days. B) Percentage of
sprouting EB and C) number of sprouts per sprouting EB were manually
measured on photomicrographs in ESC reduced in expression of
junction molecules compared to D3-ESC control. *** p-value,0.0005,
** p-value,0.005; * p-value,0.05.
doi:10.1371/journal.pone.0023810.g005
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[29] Fok, et al reported that levels of E-cadherin, in heterozygous
and homozygous knockout ESC, correlated with size of EB [11].
Similarly, ZO-1 knockdown in mouse morulas reduced blastocyst
formation in a concentration dependent manner [30]. Overall,
our ESC data suggest that E-cad, Cx43, and ZO-1 do not play
substantial roles in hematopoietic commitment prior to the Flk-1+
progenitor stage (Figure 6B), but may be involved in differentiation
decisions at or after the Flk-1+ expression stage.
Flk-1+ cells are also capable of differentiating to endothelial cells
[22,25,31]. ESC propagated in a collagen matrix containing
endothelial-specific cytokines differentiate along the endothelial
lineage, forming EB with endothelial sprouts that invade the
matrix and express the endothelial marker CD31 (PECAM) [32].
Invasion is used as a surrogate endpoint for angiogenesis [32].
Activators of angiogenesis, VEGF and FGF-2, increase the number
of EB with endothelial sprouts, while inhibitors of angiogenesis
decrease the length of endothelial sprouts on EB [32]. We show that
reduced E-cad, Cx43 and ZO-1 expression increases the frequency
ofEBwith endothelialsproutingandnumberofsproutsoneach EB.
These data suggest that E-cad, Cx43 and ZO-1 expression may act
in a negative regulatory manner to inhibit both endothelial dif-
ferentiation (more EB with sprouts) and proliferation (more sprouts
perEB). Interestingly,disruptionofZO-1 patterninginhumanESC
has been reported to increase vasculogenesis in EB [33]. Expression
of endothelial genes, Tie1 and Tie2, was not consistently altered in
engineered ESC (data not shown). Tie1 and Tie2 levels in Kd-E-
cad, Kd-Cx43 and Kd-ZO1 were similar to controls. Tie1 expression
inhibits and Tie2 expression promotes angiogenesis [34]. The Tie1
results, whichwere not consistent withinhibitionofangiogenesis, may
be complicated by expression in lineages other than endothelial cells
present in the EB [35]. Overall, however, the hematopoietic and
endothelial data suggest that E-cad, Cx43 and ZO-1 expression
influence lineage commitment at the point of endothelial and
hematopoietic divergence (Figure 6A).
We demonstrate that ZO-2 levels are important for mainte-
nance of early, intermediate and late stages of hematopoietic/
endothelial differentiation in ESC. Kd-ZO2 ESC generated fewer
Flk-1+ progenitors and hematopoietic cells than D3-ESC.
Although endothelial sprouting in Kd-ZO2 ESC was similar to
control ESC, there was an increase in number of sprouts on EB,
suggesting increased proliferation of endothelial cells. These data
suggest that low ZO-2 levels induce a block in ESC differentiation
to Flk-1+ cells, but do not perturb endothelial commitment
(Figure 6A). Although Flk-1 expression is necessary for hemato-
poietic and endothelial differentiation, Flk-1 expression has been
observed in smooth muscle cells [36], cardiomyocytes [37], retinal
progenitors [38] and other neural lineages [39]. Thus, a reduction
in the frequency of Flk-1+ cells without alterations in endothelial
commitment may suggest that endothelial cells can be generated
through alternative non-Flk-1+ populations.
Overall, our data suggest that expression of junction molecules
and their downstream components is associated with ESC
commitment decisions between hematopoietic and endothelial
lineages. Reduced expression of transmembrane junction mole-
cules, E-cad and Cx43, increased endothelial commitment and
decreased hematopoietic development, suggesting that these AM
influence a common progenitor and activate divergent pathways
towards lineage commitment (Figure 6B). Intracellular compo-
nents, ZO-1 and ZO-2 possibly regulate differentiation decisions
through additional interactions (Figure S4). For example, ZO-1
associates with components of adherens, gap and tight junction
pathways, including direct interactions with a-catenin and
connexins [16,40] as well as claudins, ZO-2, JAM1, ZONAB,
occludens and actin [14]. Expression of ZO-2 may be necessary
for commitment to Flk-1+ progenitors; whereas, ZO-1 expression
regulates later development decisions through ZONAB and a-
catenin interactions. Modulation of cell fate commitment decisions
between hematopoietic and endothelial lineages may occur
through activation of intracellular signaling pathways, prolifera-
tion of endothelial progenitors or apoptosis of hematopoietic
progenitors during EB development. Future analysis will require
identification of downstream targets of these AM pathways in
regulating hematopoietic/endothelial cell fate decisions and
proliferation/apoptosis of hematopoietic/endothelial cells during
EB development.
Finally, our data also suggest the AM may be useful as
discriminants of transitional subpopulations within the Bry, Flk-1
and Scl expressing (Figure 6B) populations. Undifferentiated ESC
express E-cad, Cx43, ZO-1 and ZO-2. As Bry transcription was
up-regulated in mesoderm cells, E-cad and ZO-2 expression was
Figure 6. Adhesion molecules expression and influence in
hematopoietic and endothelial differentiation. A) Knockdown of
junction molecules ZO-1, Cx43 and E-Cad in murine ESC results in
increased commitment to differentiate along the endothelial lineage
with concurrent loss of commitment to hematopoietic cells. These fate
decisions occur after the emergence of Flk-1 precursors in EB.
Knockdown of ZO-2 in mouse ESC reduces hematopoietic commitment
without influencing endothelial differentiation. B) Hematopoietic stages
of differentiation can be identified using intracellular and extracellular
markers. ESC undergoing mesodermal commitment express the
transcription factor Bry. As mesodermal cells become committed to
early hematopoietic and endothelial progenitors, the cell surface
receptor, Flk-1, is expressed. Scl is a transcription factor expressed as
cells commit specifically to the hematopoietic lineage. Expression of E-
cad, Cx43, ZO-1 and ZO-2 varies during early stages of hematopoietic
and endothelial differentiation of ESC.
doi:10.1371/journal.pone.0023810.g006
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constant with the Bry- populationof cells. Flk-1+ hematopoietic and
endothelial progenitors had higher levels of ZO-1 and ZO-2,
retained similar levels of Cx43 and reduced levels of E-cad than Flk-
1- subpopulation. Scl+ cells, which have committed to the
hematopoietic lineage, expressed ZO-1 in addition to the up-
regulation of E-cad, Cx43 and ZO-2. These data not only suggest
that E-cad, Cx43, ZO-1 and ZO-2 expression is associated with
commitment decisions, but also that these markers identify
subpopulations within the Bry+, Flk-1+ and Scl+ populations.
Materials and Methods
ESC Maintenance and EB Formation
Murine ESC lines D3-ESC [41], Bry-GFP [22] and Scl-LacZ
[42] were cultured on mitomycin C treated STO cells (ATCC,
Manassas, VA) as described [43]. ESC medium was exchanged
daily during maintenance and pre-differentiation. EB were
induced by culturing pre-differentiated ESC (2000–8000 cells/
mL) in EB Medium as previously described [43] for 4 to 14 days at
37uC, 5% CO2. Briefly, EB medium consisting of 1% methylcel-
lulose (Sigma, St. Louis, MO) in Iscove’s modified Dulbecco’s
medium (IMDM; Mediatech, Herndon, VA) supplemented with
15% FBS, 2 mM L-glutamine (Mediatech, Herndon, VA),
450 mM MTG, 200 mg/mL transferrin (Sigma, St. Louis, MO)
and 50 mM ascorbic acid (Sigma, St. Louis, MO) was used for
undirected hematopoietic and endothelial differentiation analysis.
EB cultures were supplemented with freshly prepared EB medium
at days 4, 8 and 12 of differentiation induction.
RNA Extraction and cDNA Synthesis
RNA was extracted from cells using Tri Reagent (Molecular
Research Center, Cincinnati, OH) following manufacturer’s
recommendations. cDNA was synthesized using M-MLV reverse
transcriptase (Fisher, Pittsburgh, PA) and random hexamers
(Fisher, Pittsburgh, PA) for priming. Reverse transcription was
completed by incubation at 25uC for 10 minutes followed by 37uC
for 60 minutes. The enzyme was heat inactivated at 70uC for
10 minutes.
Quantitative PCR
Quantitative PCR (qPCR) was performed using Brilliant SYBR
Green qPCR Master Mix (Stratagene, La Jolla, CA) on a
MX3000P qPCR System (Stratagene, La Jolla, CA) as follows:
95uC for 10 minutes; 45 cycles of 95uC for 30 seconds, 55uC for
30 seconds and 72uC for 30 seconds. The dissociation curve was
analyzed at 95uC for 1 minute, 55uC for 30 seconds and ramping
to 95uC. Relative quantification was determined with DDCt
analysis using GAPDH and untreated sample expression levels.
Primers were designed to encompass multiple exons when possible
to prevent interference from genomic DNA (Table S1).
shRNA Expression Vector Construction and Transfection
Five siRNA sequences were designed for each target (E-cad,
Cldn4, Cx43, ZO-1 and ZO-2) using siDesign Center (Dharma-
con; http://www.dharmacon.com/sidesign/default.aspx) based
on GenBank mRNA sequences. Sense and antisense siRNA
sequences were converted to shRNA cassettes as reported [44].
shRNA cassettes were ligated to entry vector, pEN-mH1c (ATCC;
Manassas, VA) at BamHI and XhoI sites. shRNA clones were
transfected into D3-ESC (ATCC; Manassas, VA) with Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA) according to manufacturer’s
recommendations.
Lentiviral Preparation and Transduction
pEN-mH1c-shRNA constructs with silencing ability were sub-
cloned into pDSL-hpUG (ATCC, Manassas, VA) destination
vector using GatewayH LR Clonase
TM (Invitrogen, Carlsbad, CA)
according to manufacturer’s recommendations. 293FT cells (Invitro-
gen, Carlsbad, CA) were transfected overnight using Lipofectamine
2000: 1 mg pDSL-hpUG-shRNA and 3 mg ViraPower Packaging
Mix (Invitrogen, Carlsbad, CA). ESC were transduced with viral
particles overnight at 37uC, 5% CO2 in ESC media supplemented
with 5 mg/ml hexadimethrine bromide (Sigma, St. Louis, MO).
Transduced cells were selected by sorting GFP+ cells on the
FACSAria (Becton Dickinson, San Jose, CA). Target silencing was
validatedbyRT-qPCR usingSYBRGreenreagents(Stratagene,La
Jolla, CA).
Colony Forming Cell Assay
EB were collected from methylcellulose media by dilution with
IMDM, 2% FBS and centrifugation. Single cell suspensions were
obtained by incubating cells at 37uC with 0.25% Trypsin/
2.21 mM EDTA (Mediatech, Herndon, VA). EB cells were
assayed for colony forming potential as described [8].
Endothelial Sprouting Assay
Endothelial sprouting assay was performed as described [32].
Briefly, 1610
4 ESC were seeded in 35 mm dishes in 1.2 mg/ml
collagen, type I (BD Bioscience, San Jose, CA) neutralized with 0.1
N NaOH. Collagen media contained 15% FBS, 450 mm MTG,
10 mg/ml insulin (Sigma, St. Louis, MO), 50 ng/ml human
vascular endothelial growth factor (VEGF; Peprotech, Rocky Hill,
NJ), 100 ng/ml human basic fibroblast growth factor (FGF-2;
Peprotech, Rocky Hill, NJ) in IMDM. Cells were incubated at
37uC, 5% CO2. At day 6, 200 ml media without collagen was added
and EB were analyzed on day 11. Image analysis was performed
using AxioVision LE Software (Zeiss, Thornwood, NY).
Flow Cytometry
EB were collected by centrifugation and single cells were
obtained by trypsinization or treatment for 20 minutes at 37uCi n
0.125% collagenase (Sigma, St. Louis, MO), 0.125% dispase
(Worthington Biochemicals, Lakewood, NJ), and 1% DNase
(Thermo Scientific, Waltham, MA) in IMDM, 10% FBS and
manual dissociation. LacZ expression in Scl-LacZ cells was
determined by flow cytometry with fluoroscein di-b-D-galactopyr-
anoside (FDG; Invitrogen, Carlsbad, CA) according to manufac-
turer’s recommendations. Briefly, cells were exposed to 300 mM
chloroquine diphosphate (Sigma, St. Louis, MO) in ESC medium
at 37uC for 20 minutes. Cells were incubated on ice with 1 mM
FDG for 1 minute. FDG loading was terminated with 10 volumes
ice cold ESC medium with 300 mM chloroquine diphosphate.
Cells were exposed for 1 hour on ice in 2% BSA to the following
antibodies: phycoerythrin (PE)-conjugated antibody to SSEA-1
(Chemicon, Temecula, CA), PE-conjugated antibody to Flk-1 (BD
Bioscience, San Jose, CA), fluoroscein isothiocyanate (FITC)-
conjugated antibody to E-cadherin (BD Bioscience, San Jose, CA)
and PerCP-Cy5.5 conjugated antibody to CD45 (BD Bioscience,
San Jose, CA). Dead cells were excluded using 2 mg/ml propidium
iodide (Sigma, St. Louis, MO) or 0.5 mg/ml 49,6-diamidino-2-
phenylindole (DAPI; Sigma, St. Louis, MO). Cells were analyzed or
sorted by FACSAria and LSRII (Becton Dickinson, San Jose, CA).
Supporting Information
Figure S1 shRNA sequences were cloned into GatewayH
Entry and Destination vectors. Lentiviral constructs constitutively
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sequences into BamHI and XhoI sites of A) pEN-mH1c vector
containing recombination sites (attL1 and attL2) flanking ubiqui-
tously expressed mouse H1 promoter (mH1). Recombination
betweenattL1/attL2and attR1/attR2onB)pDSL-hpUGlentiviral
destination vector results in C) mH1 and shRNA incorporation into
lentiviral plasmid with fluorescent reporter, GFP, constitutively
expressed under Ubi-c promoter.
(TIF)
Figure S2 Pluripotency Maintained in Knockdown ESC
lines. A) D3-ESC transduced with lentiviral constructs constitu-
tively expressing GFP and shRNA specific to E-cadherin (Kd-E-
Cad), Cx43 (Kd-Cx43), ZO1 (Kd-ZO1) and ZO2 (Kd-ZO2). GFP
fluorescence was quantified using flow cytometry. Non-viable cells
were excluded using DAPI. B) Cells were stained with SSEA-1 as a
marker of pluripotency. Non-viable cells were excluded using
DAPI. C) RNA extraction and quantitative PCR was performed
on GFP expressing cells for Oct-4 expression and normalized to
GAPDH. Expression levels reported relative to control D3-ESC.
Error bars represent standard error of the mean for n=4 samples.
(TIF)
Figure S3 Protein levels of adhesion molecules are
reduced in engineered ESC. A) Western blot analysis was
performed on knockdown ESC lines with antibodies specific to E-
cad, Cx43, ZO-1 and Actin to determine B) ratio of protein
expression to Actin compared with control D3-ESC (dashed line).
C) RNA extraction and quantitative PCR was performed on Kd-
ESC lines and Scram-GFP ESC to determine relative expression
levels of E-cad, Cx43, ZO-1 and ZO-2. Samples were normalized
to GAPDH and expressed relative to D3-ESC level (dashed line).
(TIF)
Figure S4 Junction molecules interact across multiple
pathways. Cross-talk between gap, tight and adherens junction
pathways occur through intracellular components, such as ZO-1.
Association of ZO-1 with claudins (tight junctions) isolate tran-
scription factors, such as ZONAB, from translocation into the
nucleus where regulation of genes associated with cell growth and
differentiation occurs. ZO-1 has binding domains for ZO-2,
Connexins (gap junctions) and a-catenin (adherens junction).
Interaction with a-catenin prevents assembly of cadherin/catenin
complex, allowing intracellular accumulation of b-catenin, which
translocates across the nuclear membrane to modulate expression
of genes regulating cell growth and differentiation.
(TIF)
Table S1 Adhesion molecule targets. 21 genes associated
with membrane or adhesion were chosen from reports of
differential expression between pluripotent ESC and differentiated
cells. Primers were designed between exons when possible for each
gene. (CAM=Cell Adhesion Molecule; ECM=Extracellular
Matrix; HL=Hematopoietic Lineage; JM=Junction Molecule;
R-L=Receptor-Ligand; MA=Membrane Associated).
(DOC)
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